Patient Gateway

RSS Feed

Johnson & Johnson Receives U.S. FDA Priority Review For RYBREVANT FASPRO As Potential First-In-Class EGFR- And MET-Targeted Subcutaneous Treatment For Advanced Head And Neck Cancer

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head

Case Report: transformation to SCLC from EGFR-mutated squamous cell lung carcinoma during osimertinib treatment

Promatix Biosciences Awarded Innovate UK Biomedical Catalyst Grant to Advance First-in-Class EGFR × EphA2 Cis-Bispecific ADC

Promatix Biosciences Awarded Innovate UK Biomedical Catalyst Grant to Advance First-in-Class EGFR × EphA2 Cis-Bispecific ADC

Promatix Biosciences Awarded Innovate UK Biomedical Catalyst Grant to Advance First-in-Class EGFR × EphA2 Cis-Bispecific ADC

ERK/GATAD2A/SAA1 axis drives osimertinib resistance via NF-κB and macrophage reprogramming in EGFR-mutated lung adenocarcinoma

YH42946, a novel and selective tyrosine kinase inhibitor, demonstrates potent antitumor activity against EGFR exon 20 insertion mutations and HER2 alterations in NSCLC

Otsuka to Present Pivotal Two-Year eGFR Results from the Phase 3 VISIONARY Trial of VOYXACT® (sibeprenlimab-szsi) in IgA Nephropathy (IgAN) at GlomCon Hawaii 2026